Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997692 | 0.83 | PIM2 (0.52) | PIM2RAD52PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL4992873 | 0.80 | RAD52 (0.52) | PIM2RAD52PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL4995163 | 0.77 | ALDH1A1 (0.52) | PIM2CASP1 | |
| SCHEMBL5000472 | 0.75 | CYP11B1 (0.53) | PIM2RAD52PIM1CYP11B1CYP11B2 | |
| SCHEMBL3364837 | 0.73 | PIM2 (0.72) | PIM2RAD52PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL2213805 | 0.72 | PIM2 (1.00) | PIM2RAD52PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL20460140 | 0.71 | CYP11B1 (0.60) | PIM2RAD52PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL2214405 | 0.70 | PIM2 (0.74) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL2214413 | 0.70 | PIM2 (0.74) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL4997711 | 0.70 | SORD (0.47) | PIM2RAD52CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | PIM2 1679/4885RAD52 1663/4885PIM1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.